Zynext Ventures is investing in Illexcor Therapeutics to advance the clinical development of ILX002, its lead candidate for ...

It is caused by a mutation in the HBB gene, which leads to the production ... Understanding the complications associated with SCD is essential for effective management and improving patients ...